Executive Directors
Brad O'Connor
Chief Executive Officer (CEO)
Brad O'Connor first joined CogState in April 2004 in the roles of Chief Financial Officer and Company Secretary. Since leaving PricewaterhouseCoopers in 1999 he has held senior roles at Nextec Strategic Capital, the Australian Wine Exchange (a business incubated within Toll Holdings) and Spherion Group (prior to its sale to Julia Ross). He is a member of both the Institute of Chartered Accountants in Australia and the Taxation Institute of Australia.
Non-executive directors
Martyn Myer
Chairman
Martyn Myer (BMEng, MESc, MSM) is Chairman of CogState and also chairs the Remuneration and Nomination Committee and serves on the Audit and Compliance Committee. He is President of the Howard Florey Institute of Experimental Physiology and Medicine. At the Howard Florey Institute he has participated in the transition of the Institute's research focus towards diagnostic and therapeutic neuroscience, including a focus on degenerative brain diseases. Mr Myer obtained his Master of Science in Management at MIT in Boston, and his Master of Engineering Science at Monash University, Melbourne. During the last three years, Mr Myer has also served as a director of the following other listed companies:
- Coles Myer Ltd
- Diversified United Investment Ltd
Richard Morgan
Independent non-executive director
Richard Morgan (C.Biol, MI.Biol. Dip RC Path.) is an independent non-executive director. He sits on the Audit and Compliance Committee as well as the Remuneration and Nomination Committee. Mr Morgan has over 25 years experience in pharmaceutical research and development. He has held various senior management positions within Preclinical Safety, including Head of Toxicology at Wellcome plc and International Head of Toxicology and Preclinical Outsourcing for GlaxoWellcome plc, with responsibility for staff in the UK, USA and Italy. After leaving GlaxoSmithKline plc and after a period as Interim Head of Preclinical for PowderJect Pharmaceuticals, Mr Morgan established his own consultancy company (R&B HealthCare Ltd) providing advice on Toxicology and Preclinical Discovery and Development to client companies in the UK and Australia.
David Simpson
Independent non-executive director
David Simpson (BA, Hons) is an independent non-executive Director. He is the CEO of the Bluearth Institute, a Melbourne based not-for-profit enterprise established to develop programs that promote health and fitness through increased physical activity. Previously he was Senior Partner at Doremus Communications, the largest US business to business agency. From 1985 to 2001 he held a series of senior management positions in Asia, South Africa and North America as well as Australia for the multinational advertising agency, J.WalterThompson.
Dr. Michael Wooldridge
Independent non-executive director
Dr Michael Wooldridge (MBBS, MBA BSc) is an independent non-executive director. He sits on the Audit and Compliance Committee as well as the Remuneration and Nomination Committee. Formerly Federal Health Minister, Dr. Wooldridge is currently Chairman of Neurosciences Australia, Healthsource Australia (Ministerial Advisory Committee on AIDS, Sexual Health and Hepatitis), Resonance Health, and the Cooperative Research Centre in Oral Health Science. He is also Associate Professor at the University of Melbourne. During the last three years, Dr Wooldridge has also served as a director of the following other listed companies:
- Dia-B Tech Ltd
- Resonance Health Ltd
